Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Argus Raises Amgen Target Price to $460 Amid Bullish Stance

Guavy AI Editorial Team
Instruments
AMGN
Share

Argus Research analyst Jasper Hellweg has reaffirmed his 'buy' rating for Amgen (AMGN.US), but this time with a new target price of $460. This represents an increase from his previous target of $360.

Hellweg's track record is notable, with a success rate of 56.6% and an average return of 7.5% over the past year. His ratings are based on data from TipRanks, which provides analysis and calculates analyst performance.

More on Stocks

Stocks 3m ago

Goldman Sachs Issues GS4134860 Corporate Bond with 4.25% Coupon

Stocks 4m ago

Nvidia Eyes $20B Valued Mercor Investment Amid Circular Financing Concerns

Stocks 4m ago

Nvidia Sees Record Revenue as Analysts Expect Modest Growth

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy